1700090G07Rik Inhibitors
The chemical class of 1700090G07Rik inhibitors comprises a diverse array of compounds targeting key signaling pathways involved in cellular processes associated with 1700090G07Rik. These inhibitors act on various molecular targets, including kinases and receptors, to modulate signaling cascades crucial for cellular function.
The inhibitors presented, such as rapamycin, LY294002, and U0126, exert their effects through mTOR, PI3K/Akt, and MAPK/ERK pathways, respectively. These pathways play essential roles in cell survival, growth, and proliferation, and their inhibition can impact the regulation of 1700090G07Rik-related processes. Other inhibitors like Wortmannin, SB203580, and SP600125 target PI3K, p38 MAPK, and JNK pathways, respectively, influencing cellular responses linked to 1700090G07Rik
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), a key regulator of cellular growth and metabolism. Inhibition of mTOR by rapamycin can influence pathways associated with 1700090G07Rik, as mTOR is involved in the control of protein synthesis and cell proliferation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), impacting the PI3K/Akt signaling pathway. Inhibition of PI3K by LY294002 may modulate cellular processes linked to 1700090G07Rik, as PI3K/Akt signaling plays a role in cell survival, growth, and metabolism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 (mitogen-activated protein kinase kinase), affecting the MAPK/ERK signaling pathway. Inhibition of MEK1/2 by U0126 can impact pathways associated with 1700090G07Rik, as the MAPK/ERK pathway regulates cell proliferation and differentiation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinase (PI3K), affecting PI3K/Akt signaling. Inhibition of PI3K by wortmannin may influence cellular processes linked to 1700090G07Rik, as PI3K/Akt signaling plays a role in cell survival, growth, and metabolism. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAPK (mitogen-activated protein kinase), impacting the p38 MAPK signaling pathway. Inhibition of p38 MAPK by SB203580 can modulate cellular processes associated with 1700090G07Rik, as p38 MAPK regulates various cellular responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK (c-Jun N-terminal kinase), affecting the JNK signaling pathway. Inhibition of JNK by SP600125 may impact pathways associated with 1700090G07Rik, as JNK is involved in the regulation of cell survival, apoptosis, and stress responses. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective inhibitor of MEK1/2, affecting the MAPK/ERK signaling pathway. Inhibition of MEK1/2 by trametinib can influence pathways associated with 1700090G07Rik, as the MAPK/ERK pathway regulates cell proliferation and differentiation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor targeting Raf kinases, VEGFR, and PDGFR, impacting multiple signaling pathways. Inhibition of Raf kinases by sorafenib may influence cellular processes associated with 1700090G07Rik, as Raf kinases are part of the MAPK/ERK pathway. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG-490 is a selective inhibitor of JAK2 (Janus kinase 2), affecting the JAK/STAT signaling pathway. Inhibition of JAK2 by AG-490 may modulate cellular processes linked to 1700090G07Rik, as JAK/STAT signaling plays a role in immune response, cell growth, and differentiation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of TGF-β type I receptor (ALK5), affecting the TGF-β signaling pathway. Inhibition of ALK5 by SB431542 can impact cellular processes associated with 1700090G07Rik, as TGF-β signaling is involved in the regulation of cell proliferation and differentiation. | ||||||